Live Breaking News & Updates on Axicabtagene Ciloleucel Yescarta

Stay updated with breaking news from Axicabtagene ciloleucel yescarta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CAR-T Cell Therapy Market Size to Surpass USD 14.42 Billion by 2030, exhibiting a CAGR of 18.5%

As per the report by Fortune Business Insights, the global CAR-T Cell Therapy Market size is projected to reach USD 14.42 billion in 2030, at a CAGR of 18.5% during the forecast period, 2023-2030 CAR-T Cell Therapy Market Forecast 2023-2030 Pune, India, Sept. 25, 2023 (GLOBE NEWSWIRE) Global CAR-T Cell Therapy Market Size was valued at USD 2.72 billion in 2022 and is projected to grow from USD 14.42 billion by 2030 exhibiting a CAGR of 18.5% during forecast period. The growing prevalence of c ....

United States , United Kingdom , Asia Pacific , Axicabtagene Ciloleucel Yescarta , Idecabtagene Vicleucel Abecma , Ciltacabtagene Autoleucel Carvykti , Aurora Biopharma , Tisagenlecleucel Kymriah , Lisocabtagene Maraleucel Breyanzi , Brexucabtagene Autoleucel Tecartus , National Medical Products Administration , Gilead Sciences Inc , Johnson Services Inc , Janssen Global Services , Caribou Biosciences Inc , Oncology Treatment Centers , Bristol Myers Squibb Company , Carsgentherapeutics Co Ltd China , Key Companies To Fuel Market Enhancement , Cartesian Therapeutics Inc , Jw Therapeutics Shanghai Co Ltd , Cell Therapy Market Research , Fortune Business Insights , Investigational New Drug , Free Sample , North America ,

Worldwide CAR T-Cell Therapy Industry to 2030 - Players Include Legend Biotech, Novartis & Pfizer Among Others

Share this article
Share this article
ResearchAndMarkets.com s offering.
The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient s immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy. ....

United States , South Korea , Brexucabtagene Autoleucel Tecartus , Axicabtagene Ciloleucel , Tisagenlecleucel Kymriah , Idecaptagene Cicleucel , Lisocabtagene Maraleucel , Laura Wood , Axicabtagene Ciloleucel Yescarta , Kite Pharma Inca Gilead Company , Janssen Pharmaceuticals Inc , Research Scope , Bristol Myers Squibb Company , Pfizer Inc , Legend Biotech Corporation , Technology Definition , Bluebird Bio Inc , Car Therapy Development , Bellicum Pharmaceuticals Inc , Kite Pharma Inc , Custom Research , Company Overview , Carsgen Therapeutics Ltd , Office Hours Call , Cartesian Therapeutics Inc , Research Methodology ,